¼¿ï¼º¸ðº´¿ø ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°Á : 2019-06-29 ±³À°ÀÏÀÚ : 2019-06-29
±³À°Àå¼Ò : ¼¿ï¼º¸ðº´¿ø º»°ü ÁöÇÏ1Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½ÅÀÌ½Ä ¿¬±¸È¸
´ã´çÀÚ : ½ÅÀ̽Ŀ¬±¸È¸ Áغñ»ç¹«±¹
¿¬¶ôó : 02-2258-6854
À̸ÞÀÏ :
muischwa@catholic.ac.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í »çÀüµî·Ï-Àü¹®ÀÇ(5¸¸¿ø), Àü°øÀÇ/°£È£»ç/±âŸ(2¸¸¿ø) / ÇöÀåµî·Ï-Àü¹®ÀÇ(6¸¸¿ø), Àü°øÀÇ/°£È£»ç/±âŸ(3¸¸¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-29 ´ë°´ç 08:30~08:50 Non-HLA antibodies (anti-AT1R and anti-MICA) ¹ÎÁö¿ø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-29 ´ë°´ç 08:50~09:10 Clinical application of epitope analysis ¹Ú±Ýº¸·¡(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-29 ´ë°´ç 09:10~09:30 Progression of osteoporosis after KT ¹Ú¿ì¿µ(°è¸íÀÇ´ë)
±³À°½Ã°£ 06-29 ´ë°´ç 09:30~09:50 Deceased donor with acute kidney injury ±èÁ¤È£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-29 ´ë°´ç 09:50~10:10 IgA nephropathy ÀÌÇÏÁ¤(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-29 ´ë°´ç 10:10~10:30 Focal segmental glomerulosclerosis ±èÈ¿»ó(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-29 ´ë°´ç 10:50~11:10 Everolimus with reduced CNI exposure Á¶ÀåÈñ(°æºÏÀÇ´ë)
±³À°½Ã°£ 06-29 ´ë°´ç 11:10~11:30 CTLA4-Ig vs Calcineurin inhibitors ±è¸í±Ô(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-29 ´ë°´ç 11:30~12:10 Transplant pathology based on protocol biopsy Ken Sakai(Toho University, Japan)
±³À°½Ã°£ 06-29 ´ë°´ç 12:10~12:50 Tacrolimus drug level variability Min-Ju Wu(Taichung University, Taiwan)
±³À°½Ã°£ 06-29 ´ë°´ç 13:50~14:00 Recurrent ureterolithiasis after transplantation ¹®½ÅÇ×(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 14:00~14:10 ³ú»çÀÚ °ø¿© À̽ĽÅÀå¿¡¼ ¹ß°ßµÈ º¹ÇÕ¼º ½Å³¶Á¾ ±Ç¿ÀÇö (°è¸íÀÇ´ë)
±³À°½Ã°£ 06-29 ´ë°´ç 14:10~14:20 Acute uric acid nephropathy after rejection treatment ¹Ú¿äÇÑ(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 14:20~14:30 52¼¼ ³²ÀÚ¿¡¼ ½ÅÀå ÀÌ½Ä ÈÄ ÀÌ½Ä ½Å¿¡ ¹ß»ýÇÑ °á¼® Áõ·Ê ±èÇظ®(Ãæ³²´ëÇб³º´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 14:30~14:40 Mesenchymal stem cell therapy for chronic AMR ±èÇü´ö(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 14:40~14:50 Chronic active antibody-mediated rejection Áõ·Ê 1 ±è±âÇ¥(ºÐ´ç¼¿ï´ë º´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 14:50~15:00 A Case of C4d-negative Active Antibody-Mediated Rejection in Baseline Low Titer DSA ÀÓÁ¤ÈÆ(°æºÏ´ëÇб³º´¿ø )
±³À°½Ã°£ 06-29 ´ë°´ç 15:00~15:10 Bortezomib treatment for chronic AMR ±è¼º±Ô(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 15:10~15:20 Anamnestic response¿¡ ÀÇÇÑ severe antibody-mediated rejection ±è±âÅÂ(BHSÇѼº´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 15:40~15:50 Synchronous CMV and HHV-8 gastritis ±¸Á¤»ó(ÀüºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 15:50~16:00 ¹«Áõ»ó ±Þ¼º½Å¿ì½Å¿°À¸·Î ÀÎÇÑ À̽ĽŠ±â´É °¨¼Ò À̹ÎÁ¤(¾ÆÁÖ´ëÇб³º´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 16:00~16:10 Fungal infection after KT from deceased donor ±ÇÀ±Àç(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 16:10~16:20 ½ÅÀå À̽ÄÀ» ¹ÞÀº ȯÀÚ¿¡¼ ½Å±«»ç¸¦ µ¿¹ÝÇÑ ½Å³ó¾ç ÃÖ¿øÁ¤(Ãæ³²´ëÇб³º´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 16:20~16:30 Sirolimus induced pneumonitis ¼Çý¿ø(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 16:30~16:40 ½ÅÀåÀÌ½Ä ÈÄ Àç¹ßÇÑ IgA ½Åº´Áõ¿¡¼ 2ÁÖ¸¶´Ù ½ºÅ×·ÎÀÌµå °í¿ë·® Ä¡·á¸¦ ÇÏ¿© È£ÀüµÈ ȯÀÚ 2¿¹ À±Á¤¾Æ(¼¿ï ¾Æ»êº´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 16:40~16:50 KT in small bowel transplant recipient À̼ö¾Æ(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 06-29 ´ë°´ç 16:50~17:00 KT in patient with MYH9-related disease ÀÌÈ¿µ(Á¦ÁÖ´ëÇб³º´¿ø)